TNF Pharmaceuticals, Inc. (TNFA) - Total Liabilities
Based on the latest financial reports, TNF Pharmaceuticals, Inc. (TNFA) has total liabilities worth $5.55 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TNF Pharmaceuticals, Inc. - Total Liabilities Trend (2004–2024)
This chart illustrates how TNF Pharmaceuticals, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See TNFA net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
TNF Pharmaceuticals, Inc. Competitors by Total Liabilities
The table below lists competitors of TNF Pharmaceuticals, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sahakol Equipment Public Company Limited
BK:SQ
|
Thailand | ฿5.61 Billion |
|
MEDAPP S.A. ZY -10
F:WQ1
|
Germany | €13.06 Million |
|
DGB Group NV
AS:DGB
|
Netherlands | €14.38 Million |
|
SINTEZA S.A.
RO:STZ
|
Romania | RON11.07 Million |
|
The GrowHub Limited Class A Ordinary Shares
NASDAQ:TGHL
|
USA | $5.96 Million |
|
Platina Resources Limited
F:P4R
|
Germany | €391.93K |
|
Transocean Holdings Bhd
KLSE:7218
|
Malaysia | RM18.34 Million |
|
Compass Group PLC
LSE:CPG
|
UK | GBX14.08 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down TNF Pharmaceuticals, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TNF Pharmaceuticals, Inc. stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TNF Pharmaceuticals, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TNF Pharmaceuticals, Inc. (2004–2024)
The table below shows the annual total liabilities of TNF Pharmaceuticals, Inc. from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.70 Million | +31.69% |
| 2023-12-31 | $5.09 Million | +78.87% |
| 2022-12-31 | $2.84 Million | +144.04% |
| 2021-12-31 | $1.17 Million | -48.49% |
| 2020-12-31 | $2.26 Million | +47.95% |
| 2019-12-31 | $1.53 Million | -22.48% |
| 2018-12-31 | $1.97 Million | +10.56% |
| 2017-12-31 | $1.79 Million | +5.16% |
| 2016-12-31 | $1.70 Million | +1.72% |
| 2015-12-31 | $1.67 Million | -9.50% |
| 2014-12-31 | $1.84 Million | -5.60% |
| 2013-12-31 | $1.95 Million | -7.57% |
| 2012-12-31 | $2.11 Million | +195.65% |
| 2011-12-31 | $714.78K | -43.76% |
| 2010-12-31 | $1.27 Million | +10.51% |
| 2009-12-31 | $1.15 Million | +15.48% |
| 2008-12-31 | $996.00K | -86.72% |
| 2007-12-31 | $7.50 Million | +32.22% |
| 2006-12-31 | $5.67 Million | +10.96% |
| 2005-12-31 | $5.11 Million | +19.53% |
| 2004-12-31 | $4.28 Million | -- |
About TNF Pharmaceuticals, Inc.
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rh… Read more